 Timothy Bernard
Concepts (233)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 46 | 2025 | 1287 | 4.860 |
Why?
| | Brain Ischemia | 22 | 2022 | 362 | 3.180 |
Why?
| | Cerebral Arterial Diseases | 13 | 2024 | 50 | 2.450 |
Why?
| | Fibrinolytic Agents | 6 | 2020 | 303 | 1.050 |
Why?
| | Thrombolytic Therapy | 7 | 2015 | 165 | 1.030 |
Why?
| | Magnetic Resonance Angiography | 5 | 2024 | 251 | 0.830 |
Why?
| | Pediatrics | 10 | 2019 | 1139 | 0.810 |
Why?
| | Sinus Thrombosis, Intracranial | 5 | 2026 | 25 | 0.780 |
Why?
| | Thrombophilia | 5 | 2011 | 89 | 0.760 |
Why?
| | Moyamoya Disease | 5 | 2024 | 20 | 0.750 |
Why?
| | Child | 61 | 2026 | 22979 | 0.720 |
Why?
| | Thromboembolism | 3 | 2013 | 129 | 0.630 |
Why?
| | Cerebral Arteries | 3 | 2024 | 59 | 0.610 |
Why?
| | Disease Management | 4 | 2017 | 654 | 0.580 |
Why?
| | Arteries | 4 | 2017 | 262 | 0.570 |
Why?
| | Intracranial Arterial Diseases | 2 | 2024 | 11 | 0.570 |
Why?
| | Child, Preschool | 37 | 2026 | 12016 | 0.540 |
Why?
| | Vertebral Artery Dissection | 4 | 2022 | 31 | 0.530 |
Why?
| | Cerebrovascular Disorders | 2 | 2022 | 106 | 0.510 |
Why?
| | Hospitals, Pediatric | 2 | 2020 | 571 | 0.440 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2012 | 92 | 0.430 |
Why?
| | Tissue Plasminogen Activator | 2 | 2014 | 248 | 0.420 |
Why?
| | Adolescent | 37 | 2026 | 22825 | 0.410 |
Why?
| | Infant | 28 | 2026 | 10194 | 0.400 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 196 | 0.380 |
Why?
| | Recurrence | 9 | 2022 | 1151 | 0.380 |
Why?
| | Anticoagulants | 6 | 2020 | 751 | 0.380 |
Why?
| | Migraine with Aura | 1 | 2012 | 6 | 0.360 |
Why?
| | Neuroimaging | 4 | 2024 | 309 | 0.350 |
Why?
| | Risk Factors | 16 | 2026 | 11017 | 0.350 |
Why?
| | Cerebral Revascularization | 3 | 2024 | 22 | 0.340 |
Why?
| | Edema | 1 | 2012 | 128 | 0.330 |
Why?
| | Humans | 68 | 2026 | 147293 | 0.330 |
Why?
| | Arterial Occlusive Diseases | 2 | 2010 | 90 | 0.330 |
Why?
| | Infant, Newborn | 18 | 2025 | 6543 | 0.330 |
Why?
| | Venous Thrombosis | 2 | 2016 | 199 | 0.330 |
Why?
| | Blood Coagulation Disorders | 1 | 2012 | 198 | 0.320 |
Why?
| | Disease Progression | 2 | 2018 | 2890 | 0.310 |
Why?
| | Prognosis | 9 | 2020 | 4383 | 0.310 |
Why?
| | Venous Thromboembolism | 2 | 2014 | 330 | 0.300 |
Why?
| | Vertebral Artery | 2 | 2022 | 26 | 0.300 |
Why?
| | Quality of Health Care | 1 | 2014 | 697 | 0.290 |
Why?
| | Clinical Trials as Topic | 1 | 2014 | 1072 | 0.280 |
Why?
| | Thrombosis | 1 | 2012 | 401 | 0.280 |
Why?
| | Brain Infarction | 2 | 2018 | 23 | 0.260 |
Why?
| | Cerebral Angiography | 5 | 2024 | 122 | 0.250 |
Why?
| | Overweight | 1 | 2012 | 617 | 0.250 |
Why?
| | Biomarkers | 5 | 2016 | 4351 | 0.240 |
Why?
| | Neurology | 1 | 2008 | 117 | 0.240 |
Why?
| | Research Design | 1 | 2012 | 1157 | 0.240 |
Why?
| | Age of Onset | 6 | 2020 | 568 | 0.240 |
Why?
| | Cohort Studies | 10 | 2021 | 6099 | 0.230 |
Why?
| | Prostheses and Implants | 1 | 2007 | 137 | 0.230 |
Why?
| | Age Factors | 8 | 2025 | 3372 | 0.220 |
Why?
| | Retrospective Studies | 17 | 2024 | 17560 | 0.220 |
Why?
| | Male | 35 | 2026 | 73950 | 0.220 |
Why?
| | Intracranial Aneurysm | 3 | 2022 | 106 | 0.220 |
Why?
| | Embolization, Therapeutic | 1 | 2007 | 246 | 0.210 |
Why?
| | Female | 35 | 2026 | 80076 | 0.210 |
Why?
| | Adenosine Deaminase | 1 | 2023 | 45 | 0.190 |
Why?
| | Infarction, Middle Cerebral Artery | 2 | 2022 | 41 | 0.190 |
Why?
| | Mydriasis | 1 | 2022 | 10 | 0.180 |
Why?
| | Follow-Up Studies | 6 | 2026 | 5476 | 0.180 |
Why?
| | Multicenter Studies as Topic | 2 | 2014 | 417 | 0.170 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2023 | 376 | 0.170 |
Why?
| | Treatment Outcome | 11 | 2024 | 11947 | 0.170 |
Why?
| | C-Reactive Protein | 2 | 2016 | 430 | 0.160 |
Why?
| | Anesthetics | 1 | 2022 | 100 | 0.160 |
Why?
| | Guidelines as Topic | 2 | 2020 | 268 | 0.160 |
Why?
| | Hospitals, Special | 1 | 2020 | 8 | 0.160 |
Why?
| | Incidence | 6 | 2021 | 2954 | 0.160 |
Why?
| | Athletic Injuries | 1 | 2007 | 576 | 0.160 |
Why?
| | Reproducibility of Results | 5 | 2016 | 3448 | 0.160 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2021 | 96 | 0.160 |
Why?
| | Cerebral Infarction | 2 | 2020 | 47 | 0.150 |
Why?
| | Mechanical Thrombolysis | 1 | 2019 | 5 | 0.150 |
Why?
| | Colorado | 5 | 2017 | 4591 | 0.140 |
Why?
| | Obesity | 1 | 2012 | 3149 | 0.140 |
Why?
| | Streptococcal Infections | 1 | 2021 | 178 | 0.140 |
Why?
| | Sinusitis | 1 | 2021 | 230 | 0.140 |
Why?
| | Epilepsy | 1 | 2023 | 399 | 0.140 |
Why?
| | Intracranial Thrombosis | 2 | 2016 | 19 | 0.140 |
Why?
| | Program Development | 1 | 2020 | 369 | 0.140 |
Why?
| | Inflammation | 1 | 2009 | 2920 | 0.130 |
Why?
| | Carotid Stenosis | 2 | 2018 | 107 | 0.130 |
Why?
| | Prospective Studies | 7 | 2025 | 8164 | 0.130 |
Why?
| | Smith-Magenis Syndrome | 1 | 2017 | 2 | 0.130 |
Why?
| | Recovery of Function | 2 | 2020 | 724 | 0.120 |
Why?
| | Diagnostic Imaging | 3 | 2009 | 342 | 0.120 |
Why?
| | Serum Amyloid A Protein | 1 | 2016 | 32 | 0.120 |
Why?
| | Observer Variation | 3 | 2011 | 358 | 0.120 |
Why?
| | Surveys and Questionnaires | 2 | 2021 | 6164 | 0.120 |
Why?
| | Cerebral Veins | 1 | 2016 | 16 | 0.120 |
Why?
| | Peroxidase | 1 | 2016 | 168 | 0.120 |
Why?
| | Hippocampus | 2 | 2018 | 989 | 0.120 |
Why?
| | Cavernous Sinus Thrombosis | 1 | 2015 | 8 | 0.110 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 2133 | 0.110 |
Why?
| | Encephalitis | 1 | 2017 | 142 | 0.110 |
Why?
| | Neurosurgical Procedures | 1 | 2017 | 207 | 0.110 |
Why?
| | Alagille Syndrome | 1 | 2014 | 29 | 0.110 |
Why?
| | Prevalence | 4 | 2022 | 2889 | 0.110 |
Why?
| | Genetic Predisposition to Disease | 1 | 2023 | 2458 | 0.100 |
Why?
| | National Institutes of Health (U.S.) | 2 | 2011 | 149 | 0.100 |
Why?
| | Hyperhomocysteinemia | 1 | 2013 | 26 | 0.100 |
Why?
| | Methylenetetrahydrofolate Reductase (NADPH2) | 1 | 2013 | 36 | 0.100 |
Why?
| | Registries | 4 | 2020 | 2434 | 0.100 |
Why?
| | Magnetic Resonance Imaging | 6 | 2022 | 3980 | 0.100 |
Why?
| | Apoprotein(a) | 1 | 2013 | 8 | 0.100 |
Why?
| | Proteomics | 2 | 2023 | 1203 | 0.090 |
Why?
| | Health Expenditures | 1 | 2014 | 199 | 0.090 |
Why?
| | ADAM Proteins | 1 | 2012 | 65 | 0.090 |
Why?
| | Quality Control | 1 | 2012 | 161 | 0.090 |
Why?
| | Lipoprotein(a) | 1 | 2013 | 70 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2014 | 252 | 0.090 |
Why?
| | Pandemics | 3 | 2026 | 1720 | 0.090 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 1224 | 0.080 |
Why?
| | Mass Spectrometry | 1 | 2014 | 728 | 0.080 |
Why?
| | Heart Diseases | 1 | 2014 | 341 | 0.080 |
Why?
| | Middle Cerebral Artery | 2 | 2022 | 57 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 522 | 0.080 |
Why?
| | Anemia, Sickle Cell | 2 | 2011 | 322 | 0.080 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2010 | 19 | 0.080 |
Why?
| | Severity of Illness Index | 3 | 2018 | 2973 | 0.080 |
Why?
| | Asphyxia Neonatorum | 1 | 2010 | 21 | 0.080 |
Why?
| | Delphi Technique | 1 | 2011 | 347 | 0.080 |
Why?
| | Canada | 2 | 2025 | 435 | 0.080 |
Why?
| | Proteome | 1 | 2014 | 520 | 0.080 |
Why?
| | Critical Care | 1 | 2016 | 705 | 0.070 |
Why?
| | Consensus | 1 | 2011 | 476 | 0.070 |
Why?
| | Factor VIII | 1 | 2009 | 107 | 0.070 |
Why?
| | Cognition | 1 | 2017 | 1286 | 0.070 |
Why?
| | Germany | 1 | 2009 | 140 | 0.070 |
Why?
| | Acute Disease | 2 | 2009 | 1049 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1518 | 0.060 |
Why?
| | Soccer | 1 | 2007 | 40 | 0.060 |
Why?
| | Cross-Sectional Studies | 2 | 2016 | 6011 | 0.060 |
Why?
| | Brain | 3 | 2024 | 3009 | 0.060 |
Why?
| | Developmental Disabilities | 1 | 2010 | 284 | 0.060 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 742 | 0.060 |
Why?
| | Football | 1 | 2007 | 90 | 0.060 |
Why?
| | Case-Control Studies | 3 | 2025 | 3660 | 0.060 |
Why?
| | Time Factors | 3 | 2017 | 7173 | 0.060 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1776 | 0.060 |
Why?
| | Seizures | 2 | 2023 | 491 | 0.060 |
Why?
| | Secondary Prevention | 1 | 2007 | 253 | 0.060 |
Why?
| | Testosterone | 1 | 2009 | 417 | 0.060 |
Why?
| | Parents | 1 | 2014 | 1428 | 0.060 |
Why?
| | Cognition Disorders | 1 | 2010 | 551 | 0.060 |
Why?
| | Neuromyelitis Optica | 1 | 2006 | 141 | 0.050 |
Why?
| | Physical Therapy Modalities | 1 | 2008 | 346 | 0.050 |
Why?
| | Brain Injuries | 1 | 2010 | 508 | 0.050 |
Why?
| | Australia | 1 | 2025 | 299 | 0.050 |
Why?
| | Young Adult | 6 | 2024 | 14437 | 0.050 |
Why?
| | Algorithms | 1 | 2011 | 1868 | 0.050 |
Why?
| | Hereditary Autoinflammatory Diseases | 1 | 2023 | 13 | 0.050 |
Why?
| | Heart Defects, Congenital | 1 | 2011 | 941 | 0.050 |
Why?
| | United States | 6 | 2019 | 16313 | 0.050 |
Why?
| | Global Health | 2 | 2020 | 406 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2006 | 901 | 0.040 |
Why?
| | Heterozygote | 1 | 2023 | 317 | 0.040 |
Why?
| | Streptococcus anginosus | 1 | 2021 | 9 | 0.040 |
Why?
| | Muscle, Smooth | 1 | 2022 | 153 | 0.040 |
Why?
| | Syndrome | 1 | 2022 | 385 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2025 | 687 | 0.040 |
Why?
| | Mutation | 1 | 2012 | 4130 | 0.040 |
Why?
| | Vasculitis, Central Nervous System | 1 | 2020 | 16 | 0.040 |
Why?
| | Practice Guidelines as Topic | 1 | 2008 | 1598 | 0.040 |
Why?
| | Genetic Testing | 1 | 2023 | 493 | 0.040 |
Why?
| | Databases, Factual | 1 | 2025 | 1504 | 0.040 |
Why?
| | Carotid Artery Diseases | 1 | 2019 | 70 | 0.040 |
Why?
| | Association | 1 | 2019 | 12 | 0.040 |
Why?
| | Neck | 1 | 2019 | 109 | 0.040 |
Why?
| | Adult | 5 | 2023 | 41405 | 0.040 |
Why?
| | Headache | 1 | 2020 | 151 | 0.040 |
Why?
| | Anterior Cerebral Artery | 1 | 2018 | 5 | 0.040 |
Why?
| | Posterior Cerebral Artery | 1 | 2018 | 7 | 0.040 |
Why?
| | Autoantibodies | 1 | 2006 | 1513 | 0.040 |
Why?
| | Carotid Artery, Internal | 1 | 2018 | 45 | 0.030 |
Why?
| | Gastroepiploic Artery | 1 | 2017 | 4 | 0.030 |
Why?
| | Risk Assessment | 1 | 2007 | 3784 | 0.030 |
Why?
| | Computed Tomography Angiography | 1 | 2018 | 153 | 0.030 |
Why?
| | American Heart Association | 1 | 2019 | 363 | 0.030 |
Why?
| | Nervous System Diseases | 1 | 2020 | 288 | 0.030 |
Why?
| | Receptors, GABA-A | 1 | 2017 | 138 | 0.030 |
Why?
| | Odds Ratio | 2 | 2009 | 1084 | 0.030 |
Why?
| | Memory Disorders | 1 | 2017 | 198 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2017 | 195 | 0.030 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 587 | 0.030 |
Why?
| | Long-Term Potentiation | 1 | 2017 | 206 | 0.030 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 367 | 0.030 |
Why?
| | Intellectual Disability | 1 | 2017 | 183 | 0.030 |
Why?
| | Neuronal Plasticity | 1 | 2017 | 311 | 0.030 |
Why?
| | Phenotype | 1 | 2023 | 3216 | 0.030 |
Why?
| | Radiography | 1 | 2016 | 862 | 0.020 |
Why?
| | Electroencephalography | 1 | 2017 | 570 | 0.020 |
Why?
| | ADAMTS13 Protein | 1 | 2012 | 7 | 0.020 |
Why?
| | Forecasting | 1 | 2014 | 391 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 2110 | 0.020 |
Why?
| | Cost of Illness | 1 | 2014 | 327 | 0.020 |
Why?
| | Population | 1 | 2011 | 30 | 0.020 |
Why?
| | Ischemia | 1 | 2014 | 424 | 0.020 |
Why?
| | Fibrinolysis | 1 | 2013 | 164 | 0.020 |
Why?
| | Postoperative Complications | 1 | 2024 | 3022 | 0.020 |
Why?
| | Constriction, Pathologic | 1 | 2011 | 252 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2013 | 615 | 0.020 |
Why?
| | Quality of Life | 1 | 2023 | 3246 | 0.020 |
Why?
| | Risk | 1 | 2013 | 927 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2011 | 369 | 0.020 |
Why?
| | Hematocrit | 1 | 2009 | 109 | 0.020 |
Why?
| | Observation | 1 | 2009 | 54 | 0.020 |
Why?
| | Population Surveillance | 1 | 2012 | 486 | 0.020 |
Why?
| | International Cooperation | 1 | 2009 | 198 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1844 | 0.020 |
Why?
| | Intracranial Hemorrhages | 1 | 2009 | 107 | 0.020 |
Why?
| | Genotype | 1 | 2013 | 1875 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2009 | 254 | 0.020 |
Why?
| | Cholesterol | 1 | 2009 | 410 | 0.020 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2011 | 499 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2017 | 6041 | 0.020 |
Why?
| | Methylprednisolone | 1 | 2006 | 59 | 0.020 |
Why?
| | Hospitalization | 1 | 2017 | 2496 | 0.010 |
Why?
| | Multivariate Analysis | 1 | 2009 | 1550 | 0.010 |
Why?
| | Pilot Projects | 1 | 2011 | 1912 | 0.010 |
Why?
| | Neuropsychological Tests | 1 | 2010 | 1145 | 0.010 |
Why?
| | Respiratory Tract Infections | 1 | 2009 | 399 | 0.010 |
Why?
| | Sex Factors | 1 | 2009 | 2136 | 0.010 |
Why?
| | Electronic Health Records | 1 | 2011 | 1214 | 0.010 |
Why?
| | Students | 1 | 2009 | 659 | 0.010 |
Why?
| | Anti-Inflammatory Agents | 1 | 2006 | 481 | 0.010 |
Why?
| | Animals | 2 | 2017 | 38410 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18491 | 0.010 |
Why?
| | Aged | 1 | 2019 | 26514 | 0.010 |
Why?
| | Middle Aged | 1 | 2019 | 36821 | 0.010 |
Why?
|
|
Bernard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|